Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexlansoprazole MR in symptomatic nonerosive GERD
NCT00321984Phase 3Completed
- Sponsor
- Takeda
- Start
- Jun 2006
- Primary completion
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dexlansoprazole in gastroesophageal reflux disease (GERD) (3 arms), sponsored by Takeda. Primary endpoint: Percentage of Days With Neither Daytime Nor Nighttime Heartburn During Treatment at 4 weeks. Started Jun 2006; status: completed.
02
Drugs
dexlansoprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT00321984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00321984.